Trial reportEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2013
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies.
Trial report in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Early interventions for first onset of symptoms of mental health conditions: an umbrella review of systematic reviews.BMC medicine · 2026Pooled it
- Review: Efficacy of preventative interventions for children and adolescents at clinical high risk of psychosis - a systematic review and meta-analysis of intervention studies.Child and adolescent mental health · 2025Pooled it
- Interventions for prodromal stage of psychosis.The Cochrane database of systematic reviews · 2019Pooled it
- Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis.Early intervention in psychiatry · 2019Pooled it
- Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis.Schizophrenia bulletin · 2018Pooled it
- Baseline data of a sequential multiple assignment randomized trial (STEP study).Early intervention in psychiatry · 2022Trial
- Variations of blood D-serine and D-aspartate homeostasis track psychosis stages.Schizophrenia (Heidelberg, Germany) · 2024Article
- Early Detection and Prevention of Schizophrenic Psychosis-A Review.Brain sciences · 2021Review
- Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry.Frontiers in psychiatry · 2021Review
- Progression from being at-risk to psychosis: next steps.NPJ schizophrenia · 2020Review
- Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.Molecular neurobiology · 2020Article
- Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.Current treatment options in psychiatry · 2019Article
- Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review.Frontiers in psychiatry · 2018Review
- Treatment of people at ultra-high risk for psychosis.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2017Article
- Review
- Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects.The mental health clinician · 2016Article
- Altering the course of schizophrenia: progress and perspectives.Nature reviews. Drug discovery · 2016Review
- Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Neurochemical research · 2016Article
- Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophrenia.Neuropsychiatric disease and treatment · 2016Article
- Early Intervention for Psychosis with N-Methyl-D-Aspartate Receptor Modulators.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Patients meeting criteria for the risk syndrome for psychosis have treatment needs including positive and negative symptoms and cognitive impairment. These features could potentially respond to NMDA glycine-site agonists. The present objective was to determine which symptoms or domains of cognition promise to show the greatest response to glycine in risk syndrome patients. We conducted two short-term pilot studies of glycine used without adjunctive antipsychotic medication. In the first trial, 10 risk syndrome subjects received open-label glycine at doses titrated to 0.8 g/kg/d for 8 weeks, followed by discontinuation and 16 weeks of evaluation for durability of effects. In the second, 8 subjects were randomized to double-blind glycine vs. placebo for 12 weeks, followed by open-label glycine for another 12 weeks. Patients were evaluated every 1-2 weeks with the Scale Of Psychosis-risk Symptoms (SOPS) and before and after treatment with a neurocognitive battery. Within-group and between-group effect sizes were calculated. Effect sizes were large for positive (open-label within-group -1.10, double-blind between-group -1.11) and total (-1.39 and -1.15) symptoms and medium-to-large (-0.74 and -0.79) for negative symptoms. Medium or large effect sizes were also observed for several neurocognitive measures in the open-label study, although data were sparse. No safety concerns were identified. We conclude that glycine was associated with reduced symptoms with promising effect sizes in two pilot studies and a possibility of improvement in cognitive function. Further studies of agents that facilitate NMDA receptor function in risk syndrome patients are supported by these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.